Market Cap 43.07B
Revenue (ttm) 3.90B
Net Income (ttm) 887.87M
EPS (ttm) N/A
PE Ratio 49.38
Forward PE 43.77
Profit Margin 22.78%
Debt to Equity Ratio 0.43
Volume 1,870,300
Avg Vol 582,802
Day's Range N/A - N/A
Shares Out 80.42M
Stochastic %K 97%
Beta 1.49
Analysts Strong Sell
Price Target $558.30

Company Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test ki...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 207 556 0300
Fax: 207 556 4346
Address:
One IDEXX Drive, Westbrook, United States
Rajankduggy
Rajankduggy Aug. 6 at 12:01 AM
$IDXX well that was quicker than I expected …
0 · Reply
TheClockworkGroup
TheClockworkGroup Aug. 5 at 9:40 PM
$IDXX #NASDAQ | The markets are unpredictable, but with #WaveE, one of our cutting-edge #AI-driven #algorithmic #breakout #daytrading strategies, you too can make calculated trades like a pro! Scalped profits of $4,246.50 trading #IdexxLaboratoriesInc., $IDXX shares today! Experience 100% automation and compatibility with @MultiCharts, @NinjaTrader & @TradeStation...
0 · Reply
OptionWinners
OptionWinners Aug. 5 at 8:52 PM
📢 $ZTS Q2 Earnings Recap Zoetis delivered another strong quarter, beating on both top & bottom lines and raising guidance 🐶💊 💰 EPS: $1.76 vs $1.61 est → ✅ Beat by $0.15 📊 Revenue: $2.50B (+4.2% Y/Y) vs $2.41B est → ✅ Beat by $90M 📆 FY25 Guidance Raised: Revenue: $9.45B–$9.60B (was $9.43B–$9.58B) Adj. EPS: $6.30–$6.40 (was $6.20–$6.30) Organic Revenue Growth: 6.5%–8.0% Organic Adj. Net Income Growth: 5.5%–7.5% 💡 Growth led by Simparica (+17% operational), Key Dermatology (+11%), while Librela saw declines but remains a long-term focus. Shares got a boost as Zoetis continues to show broad-based strength and margin expansion 📈 #Zoetis #ZTS #Earnings #AnimalHealth #PetCare #Pharma #StockMarket #Investing #EarningsSeason #Elanco $ELAN #Idexx $IDXX #Pfizer $PFE
0 · Reply
IN0V8
IN0V8 Aug. 5 at 6:46 PM
$IDXX Opportunity BTIG raises target price to $785 from $545 Jefferies raises target price to $785 from $625 JP Morgan raises target price to $675.00 from $550.00 Morgan Stanley raises target to $722.00 from $626.00
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Aug. 5 at 4:03 PM
$IDXX expecting 100 $ drop from to 540. Entry once amd is done reporting
0 · Reply
cubie
cubie Aug. 5 at 3:52 PM
$IDXX congrats like $SPY pump yesterday, peeps took profits following day, shocker, not🙄
0 · Reply
FetchDog
FetchDog Aug. 5 at 2:21 PM
$IDXX Way over valued company. Very low growth relative to PE. Visits to vets are trending down (look at their earnings snapshot), imagine what happens when the recession gets bad. Their operating margin increase is mostly due to litigation expenses ceasing and foreign exchange. This will drop super hard on next ER as the effect of the recession starts to show. Nothing is worse for a "growth" stock than when they stop growing. 98% institutional ownership. If they wanted to buy, they bought yesterday. The price target increases were probably made in collusion with institutions so they can dump on the heads of retail.
0 · Reply
scientificway
scientificway Aug. 5 at 11:33 AM
$IDXX Small fast growing, MDXG, huge rev, eps, guidance up. , growth for sure, how much after a year
0 · Reply
TheDayTradingAcademy
TheDayTradingAcademy Aug. 5 at 10:21 AM
The U.S. health-care diagnostics company $IDXX reported Q2 results that beat expectations, sending shares higher by +27.49% on Monday at $682.78. Idexx earned $3.63 per share on revenue of $1.11 billion. Analysts expected a profit of $3.30 per share on revenue of $1.07B. The stock is up +65.15% in 2025 & +45.47% y/y, with a market cap of $54.91B.
0 · Reply
JarvisFlow
JarvisFlow Aug. 4 at 10:00 PM
JP Morgan has adjusted their stance on IDEXX Laboratories ( $IDXX ), setting the rating to Overweight with a target price of 550 → 675.
0 · Reply
Latest News on IDXX
IDEXX Laboratories Announces Second Quarter Results

Aug 4, 2025, 6:30 AM EDT - 1 day ago

IDEXX Laboratories Announces Second Quarter Results


IDEXX Laboratories: A Business With Strong Fundamentals

Jul 17, 2025, 7:06 AM EDT - 19 days ago

IDEXX Laboratories: A Business With Strong Fundamentals


IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits

May 14, 2025, 2:35 PM EDT - 2 months ago

IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits


IDEXX Laboratories Announces First Quarter Results

May 1, 2025, 6:30 AM EDT - 3 months ago

IDEXX Laboratories Announces First Quarter Results


IDEXX Laboratories: A Top Dog In The Pet Care Market

Mar 12, 2025, 6:24 AM EDT - 5 months ago

IDEXX Laboratories: A Top Dog In The Pet Care Market


IDEXX Laboratories And Its Real Value

Feb 10, 2025, 11:27 AM EST - 6 months ago

IDEXX Laboratories And Its Real Value


IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript

Feb 3, 2025, 11:26 AM EST - 6 months ago

IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript


IDEXX Announces CFO Transition

Nov 21, 2024, 7:30 AM EST - 9 months ago

IDEXX Announces CFO Transition


IDEXX Laboratories Q3: Weak End-Market Demand Continues

Nov 10, 2024, 7:50 PM EST - 9 months ago

IDEXX Laboratories Q3: Weak End-Market Demand Continues


IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 1:59 PM EDT - 9 months ago

IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript


IDEXX Laboratories Announces Third Quarter Results

Oct 31, 2024, 6:30 AM EDT - 9 months ago

IDEXX Laboratories Announces Third Quarter Results


IDEXX Laboratories to Release 2024 Third Quarter Financial Results

Sep 30, 2024, 2:00 PM EDT - 11 months ago

IDEXX Laboratories to Release 2024 Third Quarter Financial Results


IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits

Aug 11, 2024, 11:36 PM EDT - 1 year ago

IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits


Looking For Fast Growth In Healthcare? IDEXX Has You Covered

Jun 28, 2024, 5:37 PM EDT - 1 year ago

Looking For Fast Growth In Healthcare? IDEXX Has You Covered


Rajankduggy
Rajankduggy Aug. 6 at 12:01 AM
$IDXX well that was quicker than I expected …
0 · Reply
TheClockworkGroup
TheClockworkGroup Aug. 5 at 9:40 PM
$IDXX #NASDAQ | The markets are unpredictable, but with #WaveE, one of our cutting-edge #AI-driven #algorithmic #breakout #daytrading strategies, you too can make calculated trades like a pro! Scalped profits of $4,246.50 trading #IdexxLaboratoriesInc., $IDXX shares today! Experience 100% automation and compatibility with @MultiCharts, @NinjaTrader & @TradeStation...
0 · Reply
OptionWinners
OptionWinners Aug. 5 at 8:52 PM
📢 $ZTS Q2 Earnings Recap Zoetis delivered another strong quarter, beating on both top & bottom lines and raising guidance 🐶💊 💰 EPS: $1.76 vs $1.61 est → ✅ Beat by $0.15 📊 Revenue: $2.50B (+4.2% Y/Y) vs $2.41B est → ✅ Beat by $90M 📆 FY25 Guidance Raised: Revenue: $9.45B–$9.60B (was $9.43B–$9.58B) Adj. EPS: $6.30–$6.40 (was $6.20–$6.30) Organic Revenue Growth: 6.5%–8.0% Organic Adj. Net Income Growth: 5.5%–7.5% 💡 Growth led by Simparica (+17% operational), Key Dermatology (+11%), while Librela saw declines but remains a long-term focus. Shares got a boost as Zoetis continues to show broad-based strength and margin expansion 📈 #Zoetis #ZTS #Earnings #AnimalHealth #PetCare #Pharma #StockMarket #Investing #EarningsSeason #Elanco $ELAN #Idexx $IDXX #Pfizer $PFE
0 · Reply
IN0V8
IN0V8 Aug. 5 at 6:46 PM
$IDXX Opportunity BTIG raises target price to $785 from $545 Jefferies raises target price to $785 from $625 JP Morgan raises target price to $675.00 from $550.00 Morgan Stanley raises target to $722.00 from $626.00
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Aug. 5 at 4:03 PM
$IDXX expecting 100 $ drop from to 540. Entry once amd is done reporting
0 · Reply
cubie
cubie Aug. 5 at 3:52 PM
$IDXX congrats like $SPY pump yesterday, peeps took profits following day, shocker, not🙄
0 · Reply
FetchDog
FetchDog Aug. 5 at 2:21 PM
$IDXX Way over valued company. Very low growth relative to PE. Visits to vets are trending down (look at their earnings snapshot), imagine what happens when the recession gets bad. Their operating margin increase is mostly due to litigation expenses ceasing and foreign exchange. This will drop super hard on next ER as the effect of the recession starts to show. Nothing is worse for a "growth" stock than when they stop growing. 98% institutional ownership. If they wanted to buy, they bought yesterday. The price target increases were probably made in collusion with institutions so they can dump on the heads of retail.
0 · Reply
scientificway
scientificway Aug. 5 at 11:33 AM
$IDXX Small fast growing, MDXG, huge rev, eps, guidance up. , growth for sure, how much after a year
0 · Reply
TheDayTradingAcademy
TheDayTradingAcademy Aug. 5 at 10:21 AM
The U.S. health-care diagnostics company $IDXX reported Q2 results that beat expectations, sending shares higher by +27.49% on Monday at $682.78. Idexx earned $3.63 per share on revenue of $1.11 billion. Analysts expected a profit of $3.30 per share on revenue of $1.07B. The stock is up +65.15% in 2025 & +45.47% y/y, with a market cap of $54.91B.
0 · Reply
JarvisFlow
JarvisFlow Aug. 4 at 10:00 PM
JP Morgan has adjusted their stance on IDEXX Laboratories ( $IDXX ), setting the rating to Overweight with a target price of 550 → 675.
0 · Reply
cubie
cubie Aug. 4 at 8:00 PM
$IDXX they didnt have any calls above 670😅😵‍💫🤯😅
0 · Reply
KarenMoore954
KarenMoore954 Aug. 4 at 7:29 PM
$IDXX Watch the way WKSP trades today. Small pushes. Strong bid. No headlines. Someone’s accumulating the hell outta this. ⠀ Microcap. Patented tech. Gov’t contracts. And still sitting at $3.31 like it’s invisible. ⠀ That silence? It’s the prelude to a move 🔊
0 · Reply
Okadarlan
Okadarlan Aug. 4 at 6:52 PM
$IDXX Intrested in short here.
1 · Reply
Rajankduggy
Rajankduggy Aug. 4 at 6:21 PM
$IDXX Fair play on earnings but doesn’t merit a jump this high, short 678 , look to close around 630-640 , sub 620 if I see a serious bleed take place
2 · Reply
topstockalerts
topstockalerts Aug. 4 at 5:31 PM
$IDXX it took off.. 🙌 Stay tuned for more!
0 · Reply
KathleenRodriguez722
KathleenRodriguez722 Aug. 4 at 5:14 PM
$IDXX why tf is WKSP still under $ 20M cap? they got dealers, rev, IP, clean-tech stack… and its priced like a SPAC from hell this aint gonna stay quiet for long 💥
0 · Reply
Dumpster_Flame
Dumpster_Flame Aug. 4 at 5:03 PM
$IDXX take those profits before everyone else decides to
0 · Reply
LewisDaKat
LewisDaKat Aug. 4 at 4:25 PM
News out Expected earnings - IDEXX Laboratories Inc. https://marketwirenews.com/news-releases/expected-earnings-idexx-laboratories-inc--5695423437741928.html $IDXX
0 · Reply
nerp62
nerp62 Aug. 4 at 4:07 PM
$IDXX This is on a coke run.. fade coming soon! Good numbers, but not +147 good.
0 · Reply
topstockalerts
topstockalerts Aug. 4 at 3:55 PM
$IDXX it wants to squeeze higher.. ✅
0 · Reply
Cracker36
Cracker36 Aug. 4 at 3:47 PM
$IDXX ok... im in for a short....
0 · Reply
Dumpster_Flame
Dumpster_Flame Aug. 4 at 3:27 PM
$IDXX send it back below 600 $SPY $TSLA
0 · Reply